PTK2 and malignant pleural mesothelioma: Promising preclinical data in malignant pleural mesothelioma, ovarian and other solid tumours suggest that therapeutic responsiveness to FAK inhibition may be guided by Merlin loss 197, 198 or E‐cadherin levels 199.